Small Cell Lung Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Monalizumab; Drug: Carboplatin or Cisplatin; Drug: Etoposide Sponsors: Hirva Mamdani; AstraZeneca; Barbara Ann Karmanos Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Monalizumab; Drug: Carboplatin or Cisplatin; Drug: Etoposide Sponsors: Hirva Mamdani; AstraZeneca; Barbara Ann Karmanos Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Monalizumab; Drug: Carboplatin or Cisplatin; Drug: Etoposide Sponsors: Hirva Mamdani; AstraZeneca; Barbara Ann Karmanos Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Monalizumab; Drug: Carboplatin or Cisplatin; Drug: Etoposide Sponsors: Hirva Mamdani; AstraZeneca; Barbara Ann Karmanos Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer Interventions: Drug: Durvalumab; Drug: Monalizumab; Drug: Carboplatin or Cisplatin; Drug: Etoposide Sponsors: Hirva Mamdani; AstraZeneca; Barbara Ann Karmanos Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Conditions: Immunotherapy; Second-line Treatment Intervention: Drug: Cadonilimab Sponsors: Second Affiliated Hospital of Zunyi Medical University; Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou Tongren People's Hospital; The People " s Hospital of Xingyi; The Second Affiliated Hospital of Guizhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2023 Category: Research Source Type: clinical trials